Our firm advised a global pharmaceutical company on the formation of a joint venture to develop antibody and protein-based therapeutics in the areas of immunology, hematology and oncology. The collaboration model is designed to advance promising therapies quickly through the development process, using each partner’s recognized expertise, with the pharmaceutical company partner holding an exclusive option to acquire each product following the completion of Phase I trials.
July 2015
Global Pharmaceutical Company Enters Into Joint Venture to Accelerate Drug Development
Lead Contacts
